Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Novo Nordisk NOVO.B-3.93%decrease; red down pointing triangle shares fell Tuesday after Eli Lilly LLY-5.64%decrease; red down pointing triangle announced results of a new pill that could rival the ...

Novo Nordisk said it expects a decision by the fourth quarter of this year. The pharma giant already has one GLP-1 available in pill form under the name Rybelsus. The FDA cleared that drug in 2019 ...

Novo Nordisk NOVO.B3.59%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...

Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...